Publications

Our recent publications from 2022 to 2025

PubMed Link

PubMed list of publications

Google Scholar Link

Google Scholar Profile

Previous Publications

2018-2021

2011-2017

* A.C. Corresponding Author

 

  • Dylan E. Ramage, Lianne H.E. Wieske, Charlotte Crowe, Jens B. Christensen, Theo A. von Wilmowski, Drew W. Grant, Zoe Bannister, Mark A. Nakasone, Kevin Haubrich, Mark Dorward, Iva A. Tchasovnikarova, Michael P. Weekes, N. Sumru Bayin, Alessio Ciulli, Richard T. Timms. LRRC58 defines an E3 ubiquitin ligase complex sensitive to cysteine abundance. bioRxiv 2025.09.23.678073; doi: https://doi.org/10.1101/2025.09.23.678073

 

  • Valentina A. Spiteri, Dmitri Segal, Alejandro Correa-Sáez, Kentaro Iso, Ryan Casement, Miquel Muñoz i Ordoño, Mark A. Nakasone, Gajanan Sathe, Caroline Schätz, Hannah E. Peters, Mark Doward, Lisa Kainacher, Angus D. Cowan, Alessio Ciulli*, Georg E. Winter.* Dual E3 ligase recruitment by monovalent degraders enables redundant and tuneable degradation of SMARCA2/4. bioRxiv 2025.08.04.668513; doi: https://doi.org/10.1101/2025.08.04.668513

 

  • Vesna Vetma, Ilaria Puoti, Natalia Karolak, Sohini Chakraborti, Emelyne Diers, Enrico Girardi, Shakil Khan, Giorgia Kidd, Ross McLennan, Suzanne O’Connor, Nicole Trainor, Claire Whitworth, Andre Wijaya, Jeff Wong, David Zollman, William Farnaby, Johannes Popow, Alessio Ciulli*, Peter Ettmayer*, Kirsten McAulay*. Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-loaded KRAS(on) Alleles. ChemRxiv. 2025; doi: 10.26434/chemrxiv-2025-706mw. This content is a preprint and has not been peer-reviewed.

 

  • Maria Rodriguez-Rios, Conner Craigon, Mark A. Nakasone, Adam G. Bond, Mark Dorward, Anthony K. Edmonds, Mark C. Norley, Robert E. Arnold, Paul M. Wood, Stephen J. Reynolds, Joel O. Cresser-Brown, Graham P. Marsh, Hannah J. Maple, Alessio Ciulli*. BromoCatch: a self-labelling tag platform for protein analysis and live cell imaging. bioRxiv 2025.04.07.647551; doi: https://doi.org/10.1101/2025.04.07.647551

 

  • Lan, H., Hsia, O., Nakasone, M., Wijaya, A., Ciulli, A.*, Butts, C.*, Aggarwal, V.* Computation, Synthesis and NMR Investigations of PROTAC Linker Conformation, Chamaleonicity and their Impacts on the Mode of Action. ChemRxiv. 2024; doi: 10.26434/chemrxiv-2024-5dbnb. This content is a preprint and has not been peer-reviewed.

 

  • James B. Shaum, Erica A. Steen, Miquel Muñoz i Ordoño, Daniela V. Wenge, Hakyung Cheong, Moritz Hunkeler, Eric M. Bilotta, Zoe Rutter, Paige A. Barta, Natalia Milosevich, Lauren M. Hargis, Jordan Janowski, Timothy R. Bishop, Trever R. Carter, Bryce da Camara, Matthias Hinterndorfer, Lucas Dada, Wen-Ji He, Fabian Offensperger, Hirotake Furihata, Sydney R. Schweber, Charlie Hatton, Yanhe Wen, Benjamin F. Cravatt, Keary M. Engle, Bruno Melillo, Seiya Kitamura, Alessio Ciulli, Scott A. Armstrong, Eric S. Fischer, Georg E. Winter, Michael A. Erb. High-throughput diversification of protein-ligand surfaces to discover chemical inducers of proximity. bioRxiv 2024.09.30.615685; doi: https://doi.org/10.1101/2024.09.30.615685.

 

  • Ponzo, I., Solda, A., Crowe, C., Dahl, G., Geschwindner, S.*, Ciulli, A.*, Rant, U.* Proximity Biosensor Assay for PROTAC Ternary Complex Analysis. ChemRxiv. 2024; doi: 10.26434/chemrxiv-2024-8w4zb. This content is a preprint and has not been peer-reviewed.

Refereed Papers In Primary Journals

* A.C. Corresponding Author

 

2025

155. Hughes, S.J., Stec, W.J., Davies, C.T.R., McGarry, D., Williams, A., Carrara, M., Del Barco Barrantes, I., Harris, R., Tasegian, A., Owens, D.D.G., Fawcett, A., Hellicar, J., Azevedo, A., Meier, G.P., Runcie, A.C., Greger, L., O’Rourke, M., Churcher, I., Pass, M., Brown, G.A., Ciulli, A., Modis, L.K., Testa, A.

Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9.

Nat. Commun. 2025 Oct 27; 16(1):8516.

 

154. Ma, N., Bhattacharya, S., Muk, S., Jandova, Z., Schmalhorst, P.S., Ghosh, S., Le, K., Diers, E., Trainor, N., Farnaby, W., Roy, M.J., Kofink, C., Greb, P., Weinstabl, H., Ciulli, A., Bader, G., Sankar, K., Bergner, A., Vaidehi, N.

Frustration in the protein-protein interface plays a central role in the cooperativity of PROTAC ternary complexes.

Nat. Commun. 2025 Sep 29; 16(1):8595.

 

153. Dikic, I., Mayor-Ruiz, C., Winter, G.E., Koch, K., Ciulli, A.*, Thomä, N.H.

Opportunities in proximity modulation: Bridging academia and industry.

Mol. Cell. 2025 Aug 21; 85(16):3012-3022.

 

152. Lloyd, H.C., Li, Y., Payne, N.C., Zhao, Z., Xu, W., Kroupova, A., Zollman, D., Long, T., Kabir, F., Chen, M., Freeman, R., Feng, E.Y., Xi, S.Y., Hsu, Y.C., Ciulli, A., Mazitschek, R., Woo, C.M.

A method for the detection and enrichment of endogenous cereblon substrates.

Cell Chem. Biol. 2025 Aug 21; 32(8):1028-1041.e13. 

 

151. Hinterndorfer, M., Spiteri, V.A., Ciulli, A.*, Winter, G.E.*

Targeted protein degradation for cancer therapy.

Nat. Rev. Cancer. 2025 Jul; 25(7):493-516.

 

150. Vetma, V., O’Connor, S., Ciulli, A.*

Development of PROTAC degrader drugs for cancer

Annu. Rev. Cancer Biol. 2025 Apr; 9:119-140.

  • Review in Advance, 30 Oct 2024

 

149. Salerno, A., Wieske, L.H.E., Diehl, C.J., Ciulli, A.*

Rational Design of PROTAC Linkers Featuring Ferrocene as a Molecular Hinge to Enable Dynamic Conformational Changes.

J Am Chem Soc. 2025 Apr 23;147(16):13328-13344.

 

148. Usart, M., Kimmerlin, Q., Stetka, J., Stoll, C., Rai, S., Almeida Fonseca, T., Karjalainen, R., Hao-Shen, H., Roux, J., El Taher, A., Lynch, D., Makukhin, N., Ciulli, A., Skoda, R.C.

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Leukemia. 2025 Apr;39(4):876-887.

 

147. Newton, L.S., Gathmann, C., Ridewood, S., Smith, R.J., Wijaya, A.J., Hornsby, T.W., Morling, K.L., Annett, D., Chiozzi, R.Z., Reuschl, A.K., Govasli, M.L., Tan, Y.Y., Thorne, L.G., Jolly, C., Thalassinos, K., Ciulli, A., Towers, G.J., Selwood, D.L.

Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV

Nat. Commun. 2025 Feb 10;16(1):1484.

 

146. McGown, A., Vetma, V., Crepin, D., Lin, Y., Adcock, C., Craigon, C., Nafie, J., von Emloh, D., Sutton, L., Bailey, K., Edmunds, L., Sharma, M., Wilden, J.D., Coles, S.J., Tizzard, G.J., Farnaby, W., Ciulli, A., Kostakis, G.E., Spencer, J.

Use of Aldehyde–Alkyne–Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers

ACS Med. Chem. Lett. 2025 Jan 25;16(2):278-284.

 

145. Urbina, A., Hallatt, A.J., Robertson, J., Ciulli, A.*

A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)

Expert Opin. Ther. Pat. 2025 Feb 6:1-42.

 

144. Wolf, G., Craigon, C., Teoh, S.T., Essletzbichler, P., Onstein, S., Cassidy, D., Uijttewaal, E.C.H., Dvorak, V., Cao, Y., Bensimon, A., Elling, U., Ciulli, A., Superti-Furga, G.

The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells

Cell Chem. Biol. 2025 Feb 20;32(2):291-306.e6.

 

143. Alkhalaf, L.M., Arrowsmith, C., Balskus, E.P., Bergamini, G., Bhandari, R., Chang, C.J., Chen, P., Chen, X., Ciulli, A., Cricco, J.A., Davis, B.G., Delbianco, M., Dudareva, N., Dueber, E., Ferguson, F., de Giuseppe, P.O., Hamachi, I., Hammond, M.C., Hatzios, S.K., Do Heo, W., Janet, J.P., Kamat, S.S., Knapp, S., Krishnan, Y., Lang, K., Laraia, L., Leveson-Gower, R.B., Li, X.D., Liu, D.R., Liu, M.F., London, N., Mahanta, N., Mayor-Ruiz, C., Muir, T., Murakami, M.T., Rhee, H.W., Robers, M., Satz, A., Schulman, B.A., Shen, B., Shoichet, B., Strauss, E., Suzuki, T., Tiwary, P., Waldmann, H., Ward, T.R., Weeks, A., Weerapana, E., Winter, G.

Thoughts for the future

Nat. Chem. Biol. 2025 Jan;21(1):6-15.

 

2024

 

142. Lynch, D.M., Forrester, B., Webb, T., Ciulli, A.*

Unravelling the druggability and immunological roles of the SOCS-family proteins

Front. Immunol. 2024 Nov 29;15:1449397.

 

141. Tredup, C.; Ackloo, S.; Beck, H.; Brown, P.; Bullock, A.; Ciulli, A.; Dikic, I.; Edfeldt, K.; Edwards, A.; Elkins, J.; Farin, H.; Fon, E.A.; Gstaiger, M.; Günther, J.; Gustavsson, A.-L.; Häberle, S.; Isigkeit, L.; Huber, K.; Kotschy, A.; Krämer, O.; Leach, A.R. ; Marsden, B.; Matsui, H.; Merk, D.; Montel, F.; Mulder, M.; Müller, S.; Owen, D.; Proschak, E.; Röhm, S.; Stolz, A.; Sundström, M.; von Delft, F.; Willson, T.; Arrowsmith, C.H.; Knapp, S.

Toward Target 2035: EUbOPEN – a public-private partnership to enable & unlock biology in the open

RSC Med. Chem. 2024 Nov 29;16(2):457-464.

 

140. Bond, A. G.; Muñoz i Ordoño, M.; Bisbach, C. M.; Craigon, C.; Makukhin, N.; Caine, E. A.; Nagala, M.; Urh, M.; Winter, G. E.;* Riching, K. M.;* Ciulli, A.*

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera

J. Am. Chem. Soc. 2024 Dec 11;146(49):33675-33711.

 

139. Kroupova, A., Spiteri, V.A., Rutter, Z.J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., Wijaya, A.J., Rodriguez-Rios, M., Sturbaut, M., Lynch, D.M., Farnaby, W., Nakasone, M.A., Zollman, D.*, Ciulli, A.*

Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders

Nat Commun. 2024 Oct 15;15(1):8885.

  • PMID: 39406745  PMCID: PMC11480361
  • Pre-print first posted at BioRxiv on 17 January 2024; 2024.01.17.575503; doi: 1101/2024.01.17.575503
  • Featured in the UoD Stories website
  • His6-TEV-CRBN-midi (Plasmid #215330) is now available on Addgene.
  • X-ray crystallography data generated in this study have been deposited in the Protein Data Bank (PDB) under accession codes: 8RQ1 (apo CRBNmidi), 8RQ8 (CRBNmidi:mezigdomide), 8RQ9 (CRBNmidi:CFT-1297:BRD4BD2), 8RQA (CRBNmidi:lenalidomide), 8RQC (CRBNmidi:mezigdomide:IKZF1ZF2), 9GAO (CRBNmidi:compound 1).

 

138. Crowe, C., Nakasone, M.A., Chandler, S., Craigon,C., Sathe, G., Tatham, M.H., Makukhin, N., Hay, R.T., Ciulli, A.*

Mechanism of degrader-targeted protein ubiquitinability

  • PMID: 39392888  PMCID: PMC11468923
  • Pre-print first posted at BioRxiv on 5 February 2024; 2024.02.05.578957; doi: 1101/2024.02.05.578957
  • Featured in the UoD Stories website
  • Covered in Ian Churcher’s blog
  • Electron microscopy reconstructions have been deposited to the Electron Microscopy Databank (EMDB) under accession codes EMD-19569 and EMD-19567. Atomic models have been deposited to the PDB under IDs 8RWZ (Open non-crosslinked structure Brd4BD2-MZ1-(NEDD8)-CRL2VHL) and 8RX0 (Closed crosslinked structure of (NEDD8)-CRL2VHL-MZ1-Brd4BD2-Ub(G76S, K48C)-UBE2R1(C93K, S138C, C191S, C223S)-Ub).

 

137. Popow, J., Farnaby, W., Gollner, A., Kofink, C., Fischer, G., Wurm, M., Zollman, D., Wijaya, A., Mischerikow, N., Hasenoehrl, C., Prokofeva, P., Arnhof, H., Arce-Solano, S., Bell, S., Boeck, G., Diers, E., Frost, A.B., Goodwin-Tindall, J., Karolyi-Oezguer, J., Khan, S., Klawatsch, T., Koegl, M., Kousek, R., Kratochvil, B., Kropatsch, K., Lauber, A.A., McLennan, R., Olt, S., Peter, D., Petermann, O., Roessler, V., Stolt-Bergner, P., Strack, P., Strauss, E., Trainor, N., Vetma, V., Whitworth, C., Zhong, S., Quant, J., Weinstabl, H., Kuster, B., Ettmayer, P.*, Ciulli, A.*

Targeting cancer with small-molecule pan-KRAS degraders

Science 2024 Sep 20;385(6715):1338-1347.

  • PMID: 39298590
  • Pre-print first posted at BioRxiv on 26 October 2023; doi: 1101/2023.10.24.563163
  • Covered in UoD Stories website
  • Featured in the same issue of Science as Perspective “KRAS takes the road to destruction”
  • Featured in Chemical & Engineering News
  • Highlighted in Cancer Discovery Research Watch
  • Highlighted in Nature Biotechnology
  • X-ray crystallography data generated in this study have been deposited in the Protein Data Bank (PDB) under accession codes: 8QUG (KRAS-G12C in Complex with Compound 1), 8QW6 (compound 3 in complex with VCB (pVHL:ElonginC:ElonginB) and KRAS G12V C118S GDP), 8QW7 (compound 4 in complex with KRAS G12V C118S GDP and VCB), 8QVU (ACBI3 in complex with KRAS G12D C118S GDP and VCB).
  • Cryo-EM density maps have been deposited in the Electron Microscopy Databank (EMDB) under accession code EMD-18657. The atomic model is deposited to the PDB under ID 8QU8 (PROTAC-mediated complex of KRAS with VHL/Elongin-B/Elongin-C/Cullin-2/Rbx1).
  • Our pan-KRAS VHL-based PROTAC degrader ACBI3 (together with its negative control cis-ACBI3) are available from Boehringer Ingelheim’s OpnMe Portal: order for free, no strings attached!

 

136. Freemantle, J.B., Shah, D., Lynch, D.M., Ciulli, A., Hundal, H.S., Hardie, D.G.

The pro-drug C13 activates AMPK by two distinct mechanisms

Biochem. J. 2024, Sep 18;481(18):1203-1219.

 

135. Hatoyama, Y., Islam, M., Bond, A.G., Hayashi, K.-I., Ciulli, A., Kanemaki, M.T.

Combination of AID2 and BromoTag expands the utility of degron-based protein knockdowns

EMBO Rep., 2024 Sep;25(9):4062-4077.

 

134. Cavalli, A.,* Ciulli, A.*

Editorial overview: New concept in drug discovery

Curr. Opin. Struct. Biol. 2024, 88, 102911

 

133. Vetma, V., Casarez-Perez, L., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., Gerstberger, T., Greb, P., Kidd, G., Kofink, C., Puoti, I, Spiteri, V., Trainor, N., Westermaier, Y., Whitworth, C., Ciulli, A., Farnaby, W., McAulay, K., Frost, A.B., Chessum, N., Koegl, M.

Confounding Factors in Targeted Degradation of Short-Lived Proteins

ACS Chem. Biol. 2024 Jul 19;19(7):1484-1494.

 

132. Pierri, M., Liu, X., Kroupova, A., Rutter, Z., Hallatt, A.J., Ciulli, A.*

Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity

Bioorg. Med. Chem. Lett. 2024 Sep 15;110:129861.

  • PMID: 38942127
  • 2nd Most Downloaded Article in the journal (Dec 2024)
  • X-ray crystallographic atomic coordinates and structure factors are available at the Protein Data Bank (PDB) under accession codes 9EQM (pVHL:ElonginC:ElonginB complex (VCB) in complex with compound MP-1-21) and 9EQJ (VCB in complex with compound MP-1-39).

 

131. Diehl, C. J., Salerno, A., Ciulli, A.*

Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs.

Angew. Chem. Int. Ed. Engl. 2024 Jun 17;63(25):e202319456.

 

130. Hsia, O., Hinterndorfer, M., Cowan, A.D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M.A., Imrichova, H., Schätz, C., Rukavina, A., Husnjak, K., Wegner, M., Correa-Sáez, A., Craigon, C., Casement, R., Maniaci, C., Testa, A., Kaulich, M., Dikic, I., Winter, G.E.,* Ciulli, A.*

Targeted protein degradation via intramolecular bivalent glues

Nature 2024 Mar;627(8002):204-211.

2023

 

129. Ciulli, A.*, O’Connor, S.*, Chung, C.-W., Hartung, I. V., Testa, A., Daniels, D. L., Heitman, L. H.*

The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders

ChemMedChem 2023, e202300464.

 

128. Ramachandran, S., Makukhin, N., Haubrich, K., Nagala, M., Forrester, B., Lynch, D.M., Casement, R., Testa, A., Bruno, E., Gitto, R., Ciulli, A. *

Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2

Nat. Commun. 2023, 14, 6345

  • PMID: 37816714  PMCID: PMC10564737
  • Preprint version 1   DOI: 10.26434/chemrxiv-2022-bvj80
  • Preprint  version 2  DOI: 10.26434/chemrxiv-2022-bvj80-v2
  • See Figures here
  • Covered in UoD Stories and SLS News websites
  • Highlighted in Nature Chemical Biology; doi: 10.1038/s41589-024-01557-w
  • X-ray crystallographic atomic coordinates and structure factors are available at the PDB under accession codes 7ZLP (compound 9 soaked to SOCS2:ElonginC:ElonginB complex (SBC2)), 7ZLN (compound 11 soaked to SBC2), 7ZLO (compound 12 soaked to SBC2), 7ZLR (compound 13 soaked to SBC2), 7ZLS (compound 13 co-crystallized in complex with SBC2), 7ZLM (compound MN551 co-crystallized in complex with SBC2)
  • Our SOCS2 covalent inhibitor is available from MedChemExpress: unprotected MN551 for biophysical/structural studies or work ex-vivo / in cell lysates; and POM-protected cell-penetrant prodrug version MN714 for cellular studies
  • MN714 / MN551 is qualified within EUbOpen as a Chemical Probe for SOCS2, more info in the ProbeSheet

 

127. Vu, L.P., Diehl, C.J., Casement, R., Bond, A.G., Steinebach, C., Strašek, N., Bricelj, A., Perdih, A., Schnakenburg, G., Sosič, I., Ciulli, A.*, Gütschow, M*

Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1alpha (HIF-1alpha) Stabilizers

J. Med. Chem. 2023, 66 (18), 12776-12811

 

(126. Ramachandran et al. book chapter)

 

125. Liu, X. Ciulli, A.*

Proximity-Based Modalities for Biology and Medicine

ACS Cent. Sci. 2023, 9 (7), 1269–1284

 

124. Haubrich, K., Spiteri, V.A., Farnaby, W., Sobott, F., Ciulli, A.*

Breaking free from the crystal lattice: Structural biology in solution to study protein degraders

Curr. Opin. Struct. Biol., 2023, 79, 102534

 

123. Wijaya, A.J., Farnaby, W., Ciulli, A.*

Crystallization of VHL-based PROTAC-induced ternary complexes

Methods in Enzymology 2023, 681, 241–263

 

122. Hanzl, A., Casement, R., Imrichova, H., Hughes, S.J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A.*, Winter, G.E.*

Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders

Nat. Chem. Biol. 2023, 19 (3), 323-333

 

(121. Hsia & Ciulli book chapter)

2022

 

120. Kofink, C., Trainor, N., Mair, B., Wöhrle, S., Wurm, M., Mischerikow, N., Roy, M., Bader, G., Greb, P., Garavel, G., Diers, E., McLennan, R., Whitworth, C., Vetma, V., Rumpel, K., Scharnweber, M., Fuchs, J.E., Gerstberger, T., Cui, Y., Gremel, G., Chetta, P., Hopf, S., Budano, N., Rinnenthal, J., Gmaschitz, G., Mayer, M., Koegl, M., Ciulli, A., Weinstabl, H., Farnaby, W.

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Nat. Commun. 2022, 13, 5969

  • PMID: 36216795 PMCID: PMC9551036
  • Pre-print posted at ChemRxiv on 1 February 2022; DOI: 10.26434/chemrxiv-2022-q63s3
  • Covered in UoD and SLS News website
  • Featured in a Comment article by John Harling and Chris Tinworth in Nature Communication
  • X-ray co-crystal structures data have been deposited to the PDB under accession codes 7Z78 (compound 4 in complex with SMARCA2-BD), 7Z6L (VCB (pVHL:ElonginC:ElonginB complex): compound 5: SMARCA2-BD ternary complex), 7Z77 (VCB: compound 6: SMARCA2-BD ternary complex), and 7Z76 (VCB: compound 10: SMARCA2-BD ternary complex).
  • Our SMARCA2 VHL-based PROTAC degrader ACBI2 (together with its negative control cis-ACBI2) are available from Boehringer Ingelheim’s OpnMe Portal: order for free, no strings attached!
  • Find out more about ACBI2 in the Chemical Probes Portal

 

119. Cipriano, A., Milite, C., Feoli, A., Viviano, M., Pepe, G., Campiglia, P., Sarno, G., Picaud, S., Imaide, S., Makukhin, N., Filippakopoulos, P., Ciulli, A., Castellano, S., Sbardella, G.

Discovery of benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain

ChemMedChem 2022, 17 (20), e202200343

 

118. Liu, X., Kalogeropulou, A., Domingos, S., Makukhin, N., Nirujogi, R., Singh, F., Shpiro, N., Saalfrank, A., Sammler, E., Ganley, I., Moreira, R., Alessi, D.*, Ciulli, A.*

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Oral bioavailable and Blood Brain Barrier Penetrant PROTAC Degrader of Leucine Rich Repeat Kinase 2 (LRRK2)

J. Am. Chem. Soc. 2022, 144 (37), 16930–16952

 

117. Diehl, C.J., Ciulli, A.*

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.

Chem. Soc. Rev. 2022, 51, 8216-8257

 

116. Rasmussen, S.V.,Jin, J.X., Bickford, L.R., Woods, A.D., Sahm, F., Crawford, K.A., Nagamori, K., Goto, H., Torres, K.E., Sidoni, A., Rudzinski, E.R., Thway, K., Jones, R.L., Ciulli, A., Wright, H., Lathara, M., Srinivasa, G., Kannan, K., Huang, P.H., Grünewald, T.G.P., Berlow, N.E., Keller, C.

Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology

Clin. Transl. Med. 2022, 12 (7), e961

 

115. Gollner, A., Köster, M., Nicklin, P., Trieselmann, T., Klein, E., Vlach, J., Heine, C., Grundl, M., Ramharter, J., Wyatt, D., Chaturvedi, M., Ciulli, A., Carter, K.C., Müller, S., Bischoff, D., Ettmayer, P., Haaksma, E., Mack, J., McConnell, D., Stenkamp, D., Weinstabl, H., Zentgraf, M., Wood, C.R., Montel, F.

OpnMe.com: a digital initiative for sharing tools with the biomedical research community

Nat. Rev. Drug Discov. 2022, 21, 475-476

 

114. Grohmann, C., Magtoto, C.M., Walker, J.R., Chua, N.K., Gabrielyan, A., Hall, M., Cobbold, S.A., Mieruszynski, S., Brzozowski, M., Simpson, D.S., Dong, H., Dorizzi, B., Jacobsen, A.V., Morrish, E., Silke, N., Murphy, J.M., Heath, J.K., Testa, A., Maniaci, C., Ciulli, A., Lessene, G., Silke, J., Feltham, R.

Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms

Nat. Commun. 2022, 13, 2073

 

113. Cowan, A.D., Ciulli, A.*

Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory

Annu. Rev. Biochem., 2022, 91, 295-319

 

112. Webb, T., Craigon, C., Ciulli, A.*

Targeting Epigenetic Modulators Using PROTAC Degraders: Current Status and Future Perspective

Bioorg. Med. Chem. Lett. 2022, 63, 128653

 

111. Liu, X., Ciulli, A.*

Targeted protein stabilization: DUB be good to me

Nat. Chem. Biol. 2022, 18 (4), 358-359

 

110. Bharathy, N., Cleary, M.M., Kim, J-A., Nagamori, K., Crawford, K.A., Wang, E., Saha, D., Settelmeyer, T.P., Purohit, R., Skopelitis, D., Chang, K., Doran, J.A., Kirschbaum, C.W., Bharathy, S., Crews, D.W., Randolph, M.E., Karnezis, A.N., Hudson-Price, L., Dhawan, J., Michalek, J.E., Ciulli, A.,* Vakoc, C.R. & Keller, C.*

SMARCA4 biology in alveolar rhabdomyosarcoma

Oncogene 2022, 41, 1647–1656